A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack

Is this Study for You?

Let's Get Started!



Type of Study



Outpatient CTRC
University of Colorado Hospital

Principal Investigator
Photograph of Sharon Poisson,  MD

Sharon Poisson, MD

Study ID

Protocol Number: 23-0053

More information available at ClinicalTrials.gov: NCT05702034

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers